The global pharma contract sales market is expected to grow at a CAGR of 8.9% in the first half of the forecast period. In 2018, the contract detailing segment held 76% of the global pharma contract sales market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 253-page report you will receive 104 tables and 67 figures– all unavailable elsewhere.
The 253-page report provides clear detailed insight into the global pharma contract sales market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Pharma Contract Sales Market forecasts from 2019-2029
• Along with revenue prediction for the overall world market for pharma contract sales market, our investigation shows forecasts to 2029 for the following submarket by leading services:
• Contract detailing (personal promotion/field sales)
• Contract non-personal promotion, with further sub-forecasting for teledetailing, eDetailing and others
• Medical education services
• Sample management services
• This report also breaks down the revenue forecast for pharma contract sales market by therapeutic segments:
• Cardiovascular disease
• Metabolic disorders
• Oncology
• Other
• This report provides individual revenue forecasts to 2029 for these regional and national markets:
• US
• Japan
• EU5: Germany, UK, France, Italy and Spain
• BRIC: China, India, Brazil and Russia
The US, Japan, EU5 and BRIC markets are further segmented by therapeutic segments and leading services
• Our study discusses the SWOT and STEP factors of the global pharma contract sales market
• Our study also discusses factors that will drive and restrain the global pharma contract sales market
• Our study discusses issues affecting the pharma contract sales industry and market:
• Outsourced and in-house sales reps – trends and emerging sales models, including multiple channels (multichannel marketing to medical professionals)
• Services CSOs offer and benefits to drug companies outsourcing medical sales
• Maturing brands and product launches, including flexibility in field sales teams
• Legislation and new market access requirements for pharma sales representatives
• Changes to online marketing and potential for IT technologies Risk-sharing agreements
• Key account management (KAM) and medical science liaison (MSL)
• This report discusses the leading companies in pharma contract sales:
• CMIC
• IQVIA
• Marvecs
• OnCall, LLC
• Publicis Healthcare Communications Group (PHCG)
• Sofip
• Syneos Health (INC Research and inVentiv Health
• UDG Healthcare
Visiongain’s study is intended for anyone requiring commercial analyses for the global pharma contract sales market. You find data, trends and predictions.
Buy our report today Global Pharma Contract Sales Market 2019-2029: Contract Detailing, Contract Non-Personal Promotion, Medical Education Services, Sample Management Services, Teledetailing Services, Edetailing Services, Cardiovascular Disease, Metabolic Disorders, Oncology.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1 Pharma Contract Sales Overview
1.2 Why You Should Read This Report
1.3 How this Report Delivers
1.4 Main Questions Answered by this Report
1.5 Who is this Report for?
1.6 Research and Analysis Methods
1.7 Frequently Asked Questions (FAQ)
1.8 Associated Reports
1.9 About Visiongain
2. Introduction to Pharma Contract Sales Market
2.1 Defining the Market
2.2 What is a CSO?
2.3 What Services do CSOs Provide?
2.4 Marketing Channels Employed by Pharma Companies in 2018
2.5 Growing Trend of Outsourcing in the Overall Pharma Industry
2.6 Detailing: Becoming Less Relevant or is it as Important as Ever?
2.6.1 Declining Access to Doctors: Trend Continues in 2018
2.7 Large Cuts in Sales Force in Various Companies
2.8 Companies Cannot Rely Solely Upon Detailing
2.8.1 Trends Driving the Need for New Sales Models
3. Global Pharma Contract Sales Market 2019-2029
3.1 The Market in 2018
3.2 Global Pharma Contract Sales Market 2018-2024
3.2.1 Growth in the Market in Recent Years
3.3 Global Pharma Contract Sales Market 2018-2029
3.4 The Factors that Will Drive Growth in this Market: Advantages of Outsourcing Pharma Sales
3.4.1 Cost and Flexibility
3.4.2 New Technologies and Sales Models
3.4.3 Emerging Markets and Mature Brands
3.4.4 Biosimilars
3.4.5 Account Management, Medical Education and Patient Support Services
3.4.6 Market Access Complexities Provide its Own Opportunities for CSOs
3.4.7 New Drug Launches
3.4.8 CDER’s Novel Drug Approvals annually: 2014 - 2018
3.4.9 Summary
3.5 The Factors that Will Restrain Growth in this Market: Disadvantages of Outsourcing Pharma Sales
3.6 Leading Therapeutic Submarkets for Pharma Contract Sales, Forecast 2018-2029
3.7 The Rise in Pharma Contract Sales
3.8 How Will the Therapeutic Composition of the Market Change Between 2018 and 2029?
3.9 Contract Sales for Cardiovascular Drugs
3.9.1 Current Status
3.9.2 Recent Cardiovascular Drug Patent Expiries and FDA Approvals
3.9.3 Cardiovascular and Cerebrovascular Conditions are the World’s Most Fatal Diseases
3.9.4 Contract Sales for Cardiovascular Drugs: Submarket Forecast 2018-2029
3.10 Contract Sales for Metabolic Disorder Drugs
3.10.1 Current Status
3.10.2 430 Million People Expected to be Diagnosed with Diabetes by 2030
3.10.3 Contract Sales for Metabolic Disorders: Submarket Forecast 2018-2029
3.11 Contract Sales for Oncology Drugs
3.11.1 Current Status
3.11.2 Patent Expiries and Recent Approvals
3.11.3 Contract Sales for Oncology Drugs Forecast 2018-2029
4. Leading Service Sectors of the Pharma Contract Sales Market 2018-2029
4.1 The Leading Services
4.1.1 Leading Service Sectors of the Market, Forecast 2018-2029
4.1.2 How Will the Service Composition over the Market Change over the Next Ten Years?
4.2 Contract Detailing Submarket
4.2.1 Are we in the Midst of a Turnaround in Sales Rep Numbers in the Overall Pharma Industry?
4.2.2 What are the Trends in Sales Reps Employed by CSOs?
4.2.3 Detailing Services Offered by CSOs
4.2.4 CSOs will be Impacted by Declining Physician Access as Much as In-House Reps
4.2.5 Contract Detailing Submarket Forecast 2018-2029
4.2.6 Drivers and Restraints for this Dominant Service Submarket
4.3 Contract Non-Personal Promotion Submarket
4.3.1 The Benefits for both Pharma Companies and Doctors
4.3.2 Contract Non-Personal Promotion Submarket Forecast 2018-2029
4.3.3 Drivers and Restraints for Contract Non-Personal Promotion: Multichannel Marketing in the 21st Century
4.3.4 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Teledetailing and EDetailing
4.3.4.1 Contract Teledetailing Submarket: Current Status
4.3.4.2 Contract Teledetailing Submarket Forecast 2018-2029
4.3.4.3 Drivers and Restraints for Outsourced Teledetailing
4.3.4.4 Contract eDetailing Current Status
4.3.4.5 Contract eDetailing Submarket Forecast 2018-2029
4.3.4.6 Drivers and Restraints for Outsourced eDetailing
4.4 Medical Education Services Submarket Current Status
4.4.1 Medical Education Services Submarket Forecast 2018-2029
4.4.2 Medical Education Services Drivers and Restraints
4.5 Sample Management Services Submarket: Current Status
4.5.1 Sample Management Services Submarket Forecast 2018-2029
4.5.2 Drivers and Restraints for the Sample Management Services Submarket
4.5.3 J. Knipper and Company Inc.: A US Leader in Sample Management Services
4.5.3.1 Company Acquires Sample Management Divisions from Leading CSOs 2010-2014
4.5.3.2 Construction Underway for New State of the Art Distribution Centre
4.5.3.3 New Multi-Million Dollar Contact Centre Opened
4.5.3.4 New Technologies to Drive Growth over the Next Ten Years
5. Leading National Markets for Pharma Contract Sales: Regulatory and Commercial Outlook 2018-2029
5.1 Current Leading National Markets
5.2 Leading Regional Markets Forecast 2018-2029
5.3 How will the Regional Composition of the Market Change between now and 2028?
5.4 Pharma Sales Regulatory Developments
5.4.1 Physician Payment Legislation in the US, Europe and Japan
5.4.1.1 The Physician Payment Sunshine Act (PPSA)
5.4.1.2 Proposed Bill to Close a Large Loophole in the PPSA, Could Come into Effect in 2018
5.4.1.3 Physician Payments in France: Increased Scrutiny
5.4.2 Domestic and International Concerns over Bribery: Recent Legislation in the US and UK
5.4.2.1 Promotional Products in the EU: New Rules
5.4.3 New Market Access Requirements in EU5 Countries
5.4.3.1 AMNOG: Stricter Pricing for Drugs in Germany
5.4.3.2 AMNOG: Has Reduced Prices of Top Sellers by 23%
5.4.3.3 Healthcare Reform in France: Pricing and Reimbursements have been set to Change for a While, is 2018 the Year It Finally Happens?
5.4.3.4 PCTs Replaced by CCGs in the UK
5.4.3.5 Pricing in the UK: Contentious Issue
5.4.4 Overtime for Sales Reps in the US: Rule Clarifications
5.5 US Pharma Contract Sales Market
5.5.1 US Pharma Contract Sales Market Has Grown Rapidly
5.5.2 Pharma Sales Regulation in the US
5.5.3 US Pharma Contract Sales Market Forecast 2018-2029
5.6 EU5 Pharma Contract Sales Market
5.6.1 Regulating Pharma Sales in the EU
5.6.2 Overall EU5 Pharma Contract Sales Market Forecast 2018-2029
5.6.3 UK Pharma Contract Sales Market Forecast 2018-2029
5.6.4 German Pharma Contract Sales Market Forecast 2018-2029
5.6.5 French Pharma Contract Sales Market Forecast 2018-2029
5.6.6 Italian Pharma Contract Sales Market Forecast 2018-2029
5.6.7 Spanish Pharma Contract Sales Market Forecast 2018-2029
5.7 Japanese Pharma Contract Sales Market
5.7.1 Regulation
5.7.2 Current Market Landscape
5.7.3 Japanese Pharma Contract Sales Market Forecast 2018-2029
6. Leading Emerging Markets for Pharma Contract Sales: Regulatory and Commercial Outlook 2018-2029
6.1 Pharma Contract Sales in Leading Emerging Markets in 2018
6.2 BRIC Pharma Contract Sales Markets Forecast 2018-2029
6.3 Chinese Pharma Contract Sales Market
6.3.1 Current Pharma Contract Sales Landscape in China
6.3.2 Rising In-House and Outsourced Sales Numbers
6.3.3 Concerns over Bribery
6.3.4 Chinese Pharma Contract Sales Market Forecast 2018-2029
6.4 Indian Pharma Contract Sales Market
6.4.1 Current Pharma Contract Landscape in India
6.4.2 Government and Regulatory Guidelines for Interactions between Healthcare Professionals and Pharma Companies
6.4.3 Indian Pharma Contract Sales Market Forecast 2018-2029
6.5 Brazilian Pharma Contract Sales Market
6.5.1 Current Pharma Contract Sales Landscape in Brazil
6.5.2 State Payment Rules and Online Marketing Rules for Prescription Drugs
6.5.3 Brazilian Pharma Contract Sales Market Forecast 2018-2029
6.6 Russian Pharma Contract Sales Market
6.6.1 Current Pharma Contract Sales Landscape in Russia
6.6.2 New State Procurement Rules for Drugs Introduced in 2013
6.6.3 Tougher Rules on Interactions between Doctors and Sales Reps in Russia
6.6.4 Russian Pharma Contract Sales Market Forecast 2018-2029
7. Pharma Contract Sales: Industry and Market Trends 2018-2029
7.1 Strengths and Weaknesses for the Global Pharma Contract Sales Market 2018-2029
7.2 Opportunities and Threats for the Global Pharma Contract Sales Market 2018-2029
7.3 Pharma Contract Sales Market: STEP Analysis 2018-2029
7.3.1 Social Factors Affecting Pharma Contract Sales to 2028
7.3.1.1 The Role of Ethics in Pharma Sales
7.4 Technological Developments to Improve Sales Strategies
7.4.1 Advantages of Using Tablets and Smartphones for Detailing
7.4.1.1 CSOs Need to Maximise on the Benefits of New Technologies
7.4.2 Closed Loop Marketing (CLM)
7.4.3 Customer Relationship Management (CRM)
7.4.4 The Advantages of Cloud Computing in Pharma Contract Sales
7.4.5 Does Big Data Have a Role in Pharma Sales?
7.4.6 Social Media in Relation to Pharma Sales
7.4.6.1 FDA Releases Long-Awaited Guidance on the use of Social Media
7.4.6.2 Pharma Industry is not Using Social Media to its Full Potential, but it offers many Benefits
7.5 Economic Pressures are Limiting Healthcare and Marketing Budgets
7.6 Political Issues: Stricter Regulations for Pharma Sales around the World
7.7 Trends in Pharma Contract Sales 2018-2029
7.7.1 Cuts to In-House Sales Staff Will Continue 2018-2029
7.7.2 There will be in an Increase in Strategic Partnering in Order to Provide Long-Term Revenue Growth
7.7.3 Leading CSOs have consolidated, and will continue to Consolidate, in Order to Increase Market Penetration
7.7.4 CSOs and Pharma Clients Alike Need to Stay Vigilant about the Risks of Outsourcing Pharma Sales
7.8 Drug Development Trends Affecting Pharma Sales 2018-2029
7.8.1 How will Orphan Drug Diseases Influence Pharma Contract Sales?
7.8.2 Promotion for Biosimilar Drugs over the Next Ten Years
7.8.3 There will be Greater Demand for Specialty Medicines
7.8.4 Emerging National Markets are Becoming Increasingly Important
7.9 Sales Models Need to Evolve
7.9.1 Why are Sales Reps Struggling for Access?
7.9.1.1 One way to Fight Against Reduced Access is to Target the System as a Whole
7.9.1.2 Multichannel Marketing to Overcome Problems of Access
7.9.2 Key Account Management (KAM)
7.9.3 Silos in Sales and Marketing
7.9.4 The Use of KOLs in Pharma Sales
7.10 Market Access
7.10.1 Emerging Stakeholders in Pharma Sales
7.10.2 The Rise of ACOs
7.10.2.1 20% of US Hospitals were Part of an ACO in 2014
7.10.3 Market Access in the EU Over the Next Ten Years
7.10.4 CSOs and Market Access Consulting
7.11 Summary: Main Trends Shaping Pharma Contract Sales 2018-2029
8. Leading Contract Sales Organisations (CSOs)
8.1 Current Industry Landscape
8.2 IQVIA HOLDINGS INC. (Quintiles & IMS)
8.2.1 World Market Leader for Contract Sales and Market Access
8.2.2 New Services and Strategic Partnerships
8.2.3 IQVIA Integrated Health Services Segment Performance 2010-2015
8.2.4 IQVIA Performance 2014-2018
8.2.5 Outlook for QuintilesIMS Contract Sales to 2028
8.2.6 QuintilesIMS Financial Performance Quarterly Review 2018
8.3 UDG Healthcare
8.3.1 Global Service Provider with Various Business Units
8.3.2 Geographic and Service Growth Through Acquisitions
8.3.3 Joint Venture with CMIC
8.3.4 UDG Healthcare Financial Performance 2014-2018 and Beyond
8.4 inVentiv Health (Syneos Health)
8.4.1 Combined CRO and CCO
8.4.2 Global Structure
8.4.3 inVentiv Health Presence in US, EU and Asia
8.4.4 Possible $500m IPO in the Near Future
8.4.5 inVentiv Health Contract Sales Outlook to 2028
8.5 Publicis Healthcare Communications Group
8.5.1 PHCG Purchases PDI Commercial Services Business
8.5.1.1 PDI Prior to Acquisition: Broad Service Portfolio, Resources which PHCG now Acquires
8.5.1.2 PDI Past Financial Performance
8.5.2 Publicis Touchpoint Solutions
8.5.2.1 New Services in Recent Years, and Tardis Medical to be Aligned with the Company
8.6 OnCall, LLC
8.6.1 Range of Services
8.6.2 Contracts with Promius Pharma
8.7 Marvecs
8.7.1 A Local Leader in Germany
8.7.2 New Services Added in Recent Years: Sales 3.0
8.8 Sofip
8.9 CMIC
8.9.1 CSO Business in Japan Since 2000
8.10 Leading Players in China are not Just CSOs
9. Conclusions
9.1 The Global Pharma Contract Sales Market in 2018
9.1.1 Which Sectors Generated the Most Revenues in 2018?
9.1.2 Spending on Contract Sales is Highest in the US and EU
9.2 Outlook for the Pharma Contract Sales Market 2018-2029
9.2.1 Growth Trends for the Leading Submarkets 2018-2029
9.2.1.1 Therapeutic Sector Growth 2018-2029
9.3 Commercial Drivers for Pharma Contract Sales
Appendices
Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain report evaluation form
List of Tables
Table 2.1 Recent Big Pharma Sales Force Cuts, Based Upon Reports and Predictions
Table 3.1 Global Pharma Contract Sales Market: Revenues ($bn), AGR (%),
CAGR (%), 2018-2024
Table 3.2 Global Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 3.3 Pharma Contract Sales Market Segmented by Therapeutic Area:
Revenue ($bn), AGR (%), CAGR (%), 2018-2024
Table 3.4 Pharma Contract Sales Market Segmented by Therapeutic Area: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 3.5 Leading Therapeutic Submarket Shares (%), 2019-2029
Table 3.6 Selected Recent Cardiovascular Disease Drug Patent Expiries, 2018
Table 3.7 Selected Cardiovascular Drugs Going Off-Patent
2018-2025
Table 3.8 Cardiovascular Drugs Approved by the FDA in 2016
Table 3.9 Cardiovascular Drugs Approved by the FDA in 2015
Table 3.10 Cardiovascular Drugs Approved by the FDA in 2014
Table 3.11 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), % of Total Deaths, Deaths Per 100,000 Population, 2015 and 2030
Table 3.12 Cardiovascular Disease Submarket Forecast: Revenue ($bn),
AGR (%), CAGR (%), 2018-2024
Table 3.13 Cardiovascular Disease Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 3.14 Selected Metabolic Disorder Drugs Going Off-Patent 2016-2022
Table 3.15 Diabetes Prevalence in Leading National Markets,
2014
Table 3.16 Metabolic Disorders Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 3.17 Metabolic Disorders Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 3.18 Selected Recent and Future Oncology Patent Expiries, 2016
Table 3.19 Oncology Drugs Approved by the FDA in 2015
Table 3.20 Oncology Drugs Approved by the FDA in 2016
Table 3.21 Oncology Drugs Approved by the FDA in 2018
Table 3.22 Oncology Submarket Forecast: Revenue ($bn), AGR (%),
CAGR (%), 2018-2024
Table 3.23 Oncology Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), 2024-2029
Table 3.24 Selected Drugs Which Have Faced Market Access Challenges from NICE, 2013-2015
Table 4.1 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.2 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 4.3 Contract Detailing Submarket Forecast: Revenue ($bn), AGR (%),
CAGR (%), Market Share (%), 2018-2024
Table 4.4 Contract Detailing Submarket Forecast: Revenue ($bn), AGR (%),
CAGR (%), Market Share (%), 2024-2029
Table 4.5 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.6 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2024-2029
Table 4.7 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.8 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket, Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 4.9 Contract Teledetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.10 Contract Teledetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 4.11 Contract eDetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.12 Contract eDetailing Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 4.13 Medical Education Services Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.14 Medical Education Services Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 4.15 Sample Management Services Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2018-2024
Table 4.16 Sample Management Services Submarket Forecast: Revenues ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 5.1 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2018-2024
Table 5.2 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), AGR (%), CAGR (%), Market Shares (%), 2024-2029
Table 5.3 US Contract Sales Market:
Revenue ($bn), CAGR (%),1995 and 2018
Table 5.4 US Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2018-2024
Table 5.5 US Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 5.6 US Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
Table 5.7 US Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
Table 5.8 EU5 Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2018-2024
Table 5.9 EU5 Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 5.10 EU5 Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
Table 5.11 EU5 Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
Table 5.12 UK Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share, 2018-2024
Table 5.13 UK Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Market Share (%), 2024-2029
Table 5.14 German Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 5.15 German Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 5.16 French Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 5.17 French Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 5.18 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 5.19 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 5.20 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 5.21 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 5.22 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 5.23 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 5.24 Japan Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
Table 5.25 Japan Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
Table 6.1 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 6.2 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 6.3 BRIC Contract Sales Market Forecast: Revenue for Therapeutic Area ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
Table 6.4 BRIC Contract Sales Market Forecast: Revenue for Service Sectors ($bn), AGR (%), CAGR (%), Market Share, 2018-2029
Table 6.5 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 6.6 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 6.7 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 6.8 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 6.9 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 6.10 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 6.11 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share, 2018-2024
Table 6.12 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), AGR (%), CAGR (%), Global Market Share (%), 2024-2029
Table 7.1 Pharma Contract Sales Market: Strengths and Weaknesses 2018-2029
Table 7.2 Pharma Contract Sales Market: Opportunities and Threats 2018-2029
Table 7.3 Top 10 US Patent Expiries, 2015
Table 7.4 Notable US Patent Expiries, 2014
Table 7.5 Selected CRM Providers for Pharma Sales, 2016
Table 7.6 Orphan Drug Definitions in Leading Regions
Table 7.7 Orphan Drug Pipeline by Disease Area, 2013
Table 8.1 IQVIA Emerging Market Entries, 2010-2012
Table 8.2 IQVIA: Revenues ($bn), AGR (%), CAGR (%), 2014-2018
Table 8.3 QuintilesIMS: Financial Performance for Third Quarter Review 2018
Table 8.4 UDG Healthcare Group Profile, Business Units and Areas of Expertise, 2016
Table 8.5 UDG Healthcare: Revenues ($bn), AGR (%), CAGR (%), 2014-2018
Table 8.6 UDG Healthcare divisions, profit and employees
Table 8.7 inVentiv Health Commercial Division Subsidiaries, 2016
Table 8.8 PDI: Commercial Services Revenues ($bn), AGR (%), CAGR (%), 2010-2014
Table 9.1 Pharma Contract Sales Market: Revenues ($bn), CAGR (%) and Market Shares (%) by Sector, 2018, 2024, 2029
Table 9.2 Pharma Contract Sales Market: Revenues ($bn), CAGR (%) and Market Shares (%) by Therapeutic Area, 2018, 2024, 2029
List of Figures
Figure 2.1 The Services Offered by CSOs that Comprise the Pharma Contract Sales Market, 2018
Figure 2.2 Outsourcing Processes in the Pharma Industry, 2018
Figure 2.3 Trends Driving the Need for New Sales Models 2018-2029
Figure 3.1 Global Pharma Contract Sales Market: Revenues ($bn), 2018-2024
Figure 3.2 Global Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 3.3 FDA New Drug Approvals, 2012-2015
Figure 3.4 FDA New Drug Approvals, 2014-2018
Figure 3.5 Pharma Contract Sales: Market Growth Drivers, 2018-2029
Figure 3.6 Pharma Contract Sales Market: Restraints, 2018-2029
Figure 3.7 Pharma Contract Sales Market Segmented by Therapeutic Area (Line Graph): Revenue ($bn), 2018-2029
Figure 3.8 Pharma Contract Sales Market Segmented by Therapeutic Area (Area Chart): Revenue ($bn), 2018-2029
Figure 3.9 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2019
Figure 3.10 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2024
Figure 3.11 Pharma Contract Sales Market Segmented by Therapeutic Area: Market Shares (%), 2029
Figure 3.12 Projected Global Deaths from Ischaemic Heart Disease and Stroke (millions), 2015 and 2030
Figure 3.13 Cardiovascular Disease Submarket Forecast: Revenue ($bn), 2018-2029
Figure 3.14 Diabetes Prevalence in Leading National Markets, 2014
Figure 3.15 Metabolic Disorders Submarket Forecast: Revenue ($bn), 2018-2029
Figure 3.16 Oncology Submarket Forecast: Revenue ($bn), 2018-2029
Figure 4.1 Pharma Contract Sales Market Segmented by Service Sectors: Revenue ($bn), 2018-2029
Figure 4.2 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2018
Figure 4.3 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2024
Figure 4.4 Pharma Contract Sales Market Segmented by Service Sectors: Market Share (%), 2029
Figure 4.5 Contract Detailing Submarket Forecast: Revenue ($bn), 2018-2029
Figure 4.6 Contract Detailing Submarket: Drivers and Restraints, 2018-2029
Figure 4.7 Contract Non-Personal Promotion Submarket Forecast: Revenue ($bn), 2018-2029
Figure 4.8 Contract Non-Personal Promotion Submarket Drivers and Restraints, 2018-2029
Figure 4.9 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Forecast: Revenues ($bn), 2018-2029
Figure 4.10 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Market Shares (%), 2018
Figure 4.11 Further Sub-Sectors Within the Contract Non-Personal Promotion Submarket: Market Shares (%), 2029
Figure 4.12 Contract Teledetailing Submarket Forecast: Revenues ($bn), 2018-2029
Figure 4.13 Contract Teledetailing Submarket: Drivers and Restraints, 2018-2029
Figure 4.14 Contract eDetailing Submarket Forecast: Revenues ($bn),
2018-2029
Figure 4.15 Contract eDetailing Submarket Drivers and Restraints, 2018-2029
Figure 4.16 Medical Education Services Submarket Forecast: Revenues ($bn), 2018-2029
Figure 4.17 Medical Education Services Submarket: Drivers and Restraints, 2018-2029
Figure 4.18 Sample Management Services Submarket Forecast: Revenues ($bn), 2018-2029
Figure 4.19 Sample Management Services Submarket Drivers and Restraints, 2018-2029
Figure 5.1 Leading Regional Pharma Contract Sales Markets: Forecast Revenue ($bn), 2018-2029
Figure 5.2 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2018
Figure 5.3 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2024
Figure 5.4 Regional Composition of the Global Pharma Contract Sales Market: Market Shares (%), 2029
Figure 5.5 US Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 5.6 EU5 Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 5.7 Composition of the EU5 Pharma Contract Sales Market, 2018
Figure 5.8 Composition of the EU5 Pharma Contract Sales Market, 2029
Figure 5.9 UK Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 5.10 German Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 5.11 French Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 5.12 Italian Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 5.13 Spanish Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 5.14 Japanese Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 6.1 BRIC Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 6.2 BRIC Pharma Contract Sales Market Composition: Revenue ($bn), 2018
Figure 6.3 Chinese Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 6.4 Indian Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 6.5 Brazilian Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 6.6 Russian Pharma Contract Sales Market Forecast: Revenue ($bn), 2018-2029
Figure 7.1 Orphan Drug Pipeline by Disease Area, 2018
Figure 8.1 IQVIA Integrated Health Services Segment: Revenues ($bn), 2014-2018
Figure 8.2 QuintilesIMS Total Revenues ($bn), 2016-2018
Figure 8.3 UDG Healthcare: Revenues ($bn), 2014-2018
Figure 8.4 UDG Healthcare: Ashfield, Sharp and Aquilant Revenues ($bn), 2014-2018
Figure 8.5 PDI: Commercial Services Revenues ($bn), 2010-2014
Figure 9.1 Pharma Contract Sales Market: Revenues ($bn) by Sector, 2018, 2024, 2029
Figure 9.2 Pharma Contract Sales Market: Revenues ($bn), by Therapeutic Area, 2018, 2024, 2029
AbbVie
Actavis
Actelion Pharmaceuticals
Addison Whitney
Adheris Health
Akrikhin
Alexion
Allergan PLC
Amgen Inc.
Andrx Pharmaceutials, Inc.
Apple
Aralez Pharmaceuticals
Arbor Pharms Ireland
Arena Pharmaceuticals
Argon Global Healthcare Network
ARIAD
Arista
Ashfield Healthcare
Ashfield Healthcare Communications
AstraZeneca
BASF Schweiz AG
Bayer Healthcare
Berkshire Sterile Manufacturing (BSM)
Biogaran
Blue Earth Diagnostics, Ltd
Boehringer Ingelheim
Bristol-Myers Squibb
Brusilow Enterprises LLC
Campbell Alliance
Cegedim
Celesio
Celgene
Clovis Oncology, Inc.
CMIC Ashfield
Create NYC
Daiichi Sankyo
Dendreon
Depomed
Eisai
Eli Lilly
Encore Health Resources
Endo Pharmaceuticals
Expansis
Galliard
Genentech
GlaxoSmithKline
Grey Healthcare Group
Group DCA
GSW
Haymarket Media
Health Kare Pharma International
In2Focus
INC Research
Ingelheim
inVentiv Health
inVentiv Health Public Relations Group
inVentiv Health Selling Solutions
inVentiv Medical Communications
inVentiv Recruitment Solutions
inVentiv Therapeutics Institute
Invida
IQVIA
J&J
J. Knipper & Company Inc.
Janssen Biotech
Kadrige
Knowledge Point360
Kos Pharmaceuticals
Marvecs
Medical Communications Group (MCG)
MediMedia Health
Menarini
Merck & Co.
Merrimack
Microsoft
Millennium Pharmaceuticals
Mylan N.V
Navicor
Neurocrine Biosciences
NovaMed Pharmaceuticals
Novartis
Novella Clinical
Novo Nordisk A/S
OnCall
Oracle
Otsuka/Bristol-Myers Squibb
PALIO
Parexel International
PDI
Pegasus
Pfizer
Pharmagistics
Pharmexx
Polpharma
Promius Pharma
Publicis Healthcare Communications Group (PHCG)
Publicis Selling Solutions
Publicis Touchpoint Solutions
Qforma
Quantia
Quintiles
Ramco Import Export
Regulus Therapeutics Inc.
Roche
Salesforce.com
Sanofi
Sanofi Aventis
Schering-Plough
Scientific Voice
Sermo
Servier
Sinclair IS Pharma
SmartAnalyst
Smithkline Beecham
Sofip (Société de Franchise pour l'Information Pharmaceutique)
StayinFront
Symplmed Pharmaceuticals
Syneos Health
Synopia Rx
Taiho Oncology
Takeda
Tardis Medical
Temas
Tesaro
Teva Pharmaceutical Industries
The Medicines Company
United Therapeutics
Veeva
Vivus
Zuellig Group
Zuellig Pharma
List of Organizations Mentioned in the Report
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
Agência Nacional de Vigilância Sanitária (ANVISA)
Brazilian Ministério da Saúde
Centers of Medicare and Medicaid Services (CMS)
European Commission
European Federation of Pharmaceutical Industries and Associations (EFPIA)
European Promotional Product Association (EPPA)
Gesamtverband der Werbeartikel Wirtschaft e.V. (GWW)
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesenis (IQWiG)
L’Agenzia Italiana del Farmaco (AIFA)
Medical Council of India (MCI)
National Institute for Health and Care Excellence (NICE)
Organization of Pharmaceutical Producers of India (OPPI)
Pharmaceutical Research and Manufacturers of America (PhRMA)
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
